CBR4
Basic information
Region (hg38): 4:168863770-169010275
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CBR4 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 12 | 14 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | ||||
non coding | 0 | |||||
Total | 0 | 0 | 12 | 2 | 0 |
Variants in CBR4
This is a list of pathogenic ClinVar variants found in the CBR4 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
4-168877827-C-A | Benign (Mar 03, 2015) | |||
4-168877893-T-TGAGCGCGCTGGCC | Pancreatic adenocarcinoma | Uncertain significance (Mar 17, 2020) | ||
4-168877896-G-A | Pancreatic adenocarcinoma | Uncertain significance (Jun 27, 2018) | ||
4-168877897-C-T | Pancreatic adenocarcinoma | Likely benign (Oct 03, 2022) | ||
4-168877900-G-A | Pancreatic adenocarcinoma | Likely benign (Mar 17, 2018) | ||
4-168877902-T-C | PALLD-related disorder | Uncertain significance (Jan 10, 2023) | ||
4-168877902-T-G | not specified | Uncertain significance (Dec 10, 2021) | ||
4-168877903-G-A | Pancreatic adenocarcinoma | Likely benign (Jul 08, 2023) | ||
4-168877905-C-T | Pancreatic adenocarcinoma | Uncertain significance (Mar 27, 2022) | ||
4-168877906-C-T | Pancreatic adenocarcinoma | Benign (Jan 30, 2024) | ||
4-168877910-C-T | Pancreatic adenocarcinoma | Uncertain significance (Jun 08, 2022) | ||
4-168877916-G-A | Pancreatic adenocarcinoma | Uncertain significance (Sep 09, 2023) | ||
4-168877916-GC-G | Pancreatic adenocarcinoma | Uncertain significance (Jul 16, 2020) | ||
4-168877918-C-T | Pancreatic adenocarcinoma | Likely benign (Jan 24, 2023) | ||
4-168877921-C-G | Pancreatic adenocarcinoma | Likely benign (Oct 01, 2018) | ||
4-168877922-G-C | Pancreatic adenocarcinoma | Uncertain significance (Nov 15, 2021) | ||
4-168877922-G-T | Pancreatic adenocarcinoma • not specified | Uncertain significance (Jan 20, 2024) | ||
4-168877925-A-T | Pancreatic adenocarcinoma | Uncertain significance (Jun 23, 2021) | ||
4-168877929-A-T | Pancreatic adenocarcinoma | Uncertain significance (May 21, 2023) | ||
4-168877932-C-A | Pancreatic adenocarcinoma | Uncertain significance (Mar 28, 2018) | ||
4-168877932-C-T | Pancreatic adenocarcinoma | Uncertain significance (Oct 20, 2015) | ||
4-168877935-C-T | Pancreatic adenocarcinoma | Uncertain significance (Jan 27, 2022) | ||
4-168877936-C-T | Pancreatic adenocarcinoma | Likely benign (Mar 05, 2022) | ||
4-168877937-G-A | Pancreatic adenocarcinoma | Uncertain significance (May 10, 2023) | ||
4-168877937-G-C | Pancreatic adenocarcinoma | Uncertain significance (Mar 27, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CBR4 | protein_coding | protein_coding | ENST00000306193 | 5 | 146506 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00000607 | 0.276 | 125613 | 0 | 134 | 125747 | 0.000533 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.0768 | 120 | 122 | 0.980 | 0.00000575 | 1515 |
Missense in Polyphen | 35 | 37.688 | 0.92868 | 471 | ||
Synonymous | 0.145 | 44 | 45.2 | 0.973 | 0.00000220 | 475 |
Loss of Function | 0.0477 | 8 | 8.15 | 0.982 | 3.60e-7 | 119 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000644 | 0.000644 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.00363 | 0.00356 |
European (Non-Finnish) | 0.000298 | 0.000281 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.0000654 | 0.0000653 |
Other | 0.00182 | 0.00163 |
dbNSFP
Source:
- Function
- FUNCTION: The heterotetramer with HSD17B8 has NADH-dependent 3- ketoacyl-acyl carrier protein reductase activity, and thereby plays a role in mitochondrial fatty acid biosynthesis (PubMed:19571038, PubMed:25203508). Within the heterotetramer, HSD17B8 binds NADH; CBR4 binds NADPD (PubMed:25203508). The homotetramer has NADPH-dependent quinone reductase activity (PubMed:19000905). Both homotetramer and the heterotetramer have broad substrate specificity and can reduce 9,10- phenanthrenequinone, 1,4-benzoquinone and various other o-quinones and p-quinones (in vitro) (PubMed:19000905, PubMed:19571038, PubMed:25203508). {ECO:0000269|PubMed:19000905, ECO:0000269|PubMed:19571038, ECO:0000269|PubMed:25203508}.;
- Pathway
- Metabolism of lipids;Fatty acyl-CoA biosynthesis;Metabolism;Fatty acid metabolism
(Consensus)
Intolerance Scores
- loftool
- 0.485
- rvis_EVS
- 0.31
- rvis_percentile_EVS
- 72.23
Haploinsufficiency Scores
- pHI
- 0.216
- hipred
- N
- hipred_score
- 0.289
- ghis
- 0.562
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.145
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Cbr4
- Phenotype
Gene ontology
- Biological process
- fatty acid biosynthetic process;daunorubicin metabolic process;doxorubicin metabolic process;protein homotetramerization;protein heterotetramerization;oxidation-reduction process
- Cellular component
- mitochondrial matrix;oxidoreductase complex
- Molecular function
- NAD(P)H dehydrogenase (quinone) activity;protein binding;NADPH dehydrogenase (quinone) activity;3-oxoacyl-[acyl-carrier-protein] reductase (NADH) activity;quinone binding;NADPH binding